B+
Bull case
25%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
ZBIO
Zenas BioPharmaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-08-21 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-21
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+79.9
Score
AI commentary
The Q2 follow-up improved evidence quality through confirmed FDA acceptance, cash disclosure and dated clinical milestones, but no verified consensus surprise, analyst revisions or target changes were available. Coverage remains low and social context is absent; the appropriate stance is cautious monitoring rather than a high-conviction re-rating thesis.
RankAlpha Sentiment Codex - 2026-08-21
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-13eventPost-earnings update confirms regulatory progress and cash runwayMedium impact
The Q2 2026 update confirmed FDA acceptance of the obexelimab IgG4-RD BLA with a May 27, 2027 PDUFA date, $673.9 million of cash, equivalents and investments at June 30, and planned late-2026 clinical milestones. The release did not provide a verifiable consensus EPS or revenue comparison, so the earnings-surprise signal remains limited. [#SEC-8K-2026-08-13] [#PR-EARNINGS-2026-08-13]
2026-10-15eventEMA marketing-application submission for obexelimabHigh impact
Zenas expects to submit an MAA for IgG4-RD to the EMA in the second half of 2026. Timely submission would broaden the regulatory path; delay would weaken near-term de-risking. [#SEC-8K-2026-08-13]
2026-11-15eventSunStone Phase 2 SLE topline resultsHigh impact
Topline results from the global Phase 2 SunStone SLE trial are expected in Q4 2026. A positive readout could diversify value beyond IgG4-RD, while a miss would increase single-asset concentration risk. [#SEC-8K-2026-08-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-21 • Updated nightlySource: Internal modelMethodology